CLINDAGEL Drug Patent Profile

When do Clindagel patents expire, and what generic alternatives are available?

Clindagel is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in CLINDAGEL is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Clindagel

A generic version of CLINDAGEL was approved as clindamycin phosphate by HIKMA on April 25^th, 1988.

Summary for CLINDAGEL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	1
Patent Applications:	2,850
Drug Prices:	Drug price information for CLINDAGEL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CLINDAGEL
What excipients (inactive ingredients) are in CLINDAGEL?	CLINDAGEL excipients list
DailyMed Link:	CLINDAGEL at DailyMed

See drug prices for CLINDAGEL

See drug sales revenues for CLINDAGEL

Recent Clinical Trials for CLINDAGEL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stiefel, a GSK Company	Phase 1
GlaxoSmithKline	Phase 1

See all CLINDAGEL clinical trials

Pharmacology for CLINDAGEL

Drug Class	Lincosamide Antibacterial
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

US Patents and Regulatory Information for CLINDAGEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	CLINDAGEL	clindamycin phosphate	GEL;TOPICAL	050782-001	Nov 27, 2000	AB2	RX	Yes	Yes

Expired US Patents for CLINDAGEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	CLINDAGEL	clindamycin phosphate	GEL;TOPICAL	050782-001	Nov 27, 2000

International Patents for CLINDAGEL

See the table below for patents covering CLINDAGEL around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1109189
Spain	2326955
Spain	2437321
Japan	4988129
Hong Kong	1125847

Supplementary Protection Certificates for CLINDAGEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1304992	SPC/GB13/061	United Kingdom		PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624
1304992	CR 2013 00053	Denmark		PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
1304992	C300617	Netherlands		PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
1304992	C01304992/01	Switzerland		PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
1304992	1390049-3	Sweden		PRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322

CLINDAGEL (clindamycin phosphate) Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

CLINDAGEL is an acne drug in the topical clindamycin class, sold under brand and generic formulations across multiple regions. Demand is driven by dermatology prescribing for inflammatory acne, formulary access by pharmacy benefit managers (PBMs) and national health systems, and competitive pressure from other topical antibiotics, topical retinoids, and fixed-combination regimens. Financial trajectory since launch is defined by (1) entry of multiple generics, (2) periodic brand life-cycle moves (packaging strength and formulation updates), and (3) channel-specific reimbursement dynamics that can materially shift prescription volume even when the active ingredient remains unchanged.

What is CLINDAGEL’s market position in acne dermatology?

Therapeutic category and use case

• Indication: topical antibacterial therapy for acne vulgaris, with clindamycin phosphate used to reduce Cutibacterium acnes bacterial load and inflammation.
• Clinical positioning: typically used for mild to moderate inflammatory acne, often with or alongside benzoyl peroxide and/or topical retinoids per standard acne care patterns.

Competitive set (practical substitution risk)

CLINDAGEL competes within a crowded topical acne landscape. Key substitution channels include:

• Other topical antibiotics: e.g., topical clindamycin products (including generics) and fixed-dose combinations (often benzoyl peroxide + clindamycin).
• Non-antibiotic acne standards: topical retinoids and benzoyl peroxide monotherapy and combinations.
• Dermatology prescriber migration: when resistance or stewardship messaging influences practice, prescribers may prefer non-antibiotic regimens or fixed combinations that align with resistance-mitigation guidance.

Core market dynamic

Topical antibiotics face structural pressure because acne care guidelines promote limited antibiotic duration and preference for combination therapy. That increases churn between products even without major efficacy differences, since prescribers tune regimens to resistance stewardship, tolerability, and payer coverage.

How do generics reshape CLINDAGEL demand?

Generic entry and share dynamics

Topical clindamycin products are among the most commonly genericized acne therapies. Once generic clindamycin phosphate gels or equivalents enter, the market typically shifts in a predictable pattern:

• Brand unit share declines due to price compression.
• Prescribers remain brand-loyal in pockets only when reimbursement and formulary rules protect usage.
• Pharmacy channel carries out fast switching to lowest-cost equivalent where substitution is allowed.

Mechanism: price-to-volume elasticity in topical acne

Topical acne is high-volume and low unit price versus systemic dermatology. That structure makes demand more price sensitive at the margin:

• Net revenue declines even if prescriptions remain stable, because generic pricing compresses realized price.
• If the brand is not preferentially tiered, net revenue declines faster than prescription counts.

Channel effect

• Retail pharmacy: typically sees faster substitution to generics and co-pay driven brand switching.
• Institutional dermatology formularies: may maintain older preferred brands longer, but that is usually time-limited once reimbursement cycles shift.

What payer and formulary mechanics determine CLINDAGEL sales?

PBM and reimbursement cycle

CLINDAGEL’s financial trajectory is driven by:

• Formulary tier placement (preferred vs non-preferred).
• Patient cost-share structure (copay and coinsurance).
• Prior authorization or quantity edits (less common for topical antibiotics, but possible in some systems when acne regimens are tightly managed).

Evidence-based stewardship influences

Antibiotic stewardship guidance can indirectly shape coverage rules:

• Payers may favor fixed combinations or non-antibiotic regimens to reduce antibiotic exposure.
• Coverage can tighten for antibiotic monotherapy while allowing combinations aligned to clinical pathways.

Practical impact

Even with a stable active ingredient, payer rules change effective demand. A product can lose market position without losing clinical relevance if it stops matching payer preferred status.

What drives prescription volumes for topical clindamycin products?

Prescriber behavior

Dermatologists and general practitioners shift acne regimens based on:

• Tolerability and irritation profiles.
• Combination therapy preferences (commonly benzoyl peroxide combinations).
• Resistance stewardship and guideline adherence.

Patient adherence and usability

Gel formulation attributes affect real-world usage:

• Spreadability and dryness.
• Cosmetic acceptance and irritation rate.
• Dosing frequency and regimen complexity.

Seasonality

Acne therapies often show modest seasonality, but topical antibiotic demand is less sensitive than cosmetics-driven categories. The larger seasonal signal usually comes from changes in clinic visits and school-age demographics rather than formulation-driven demand.

How does the competitive landscape affect net revenue trajectory?

Price compression vs retention

For a brand like CLINDAGEL:

• Price compression is the default once generics are available.
• Revenue retention depends on whether the brand maintains preferred payer positioning or has formulation/packaging that sustains perceived differentiation.

Product boundary risk

Topical acne is “bundle driven.” Patients and prescribers may treat acne with a broader kit approach:

• If a patient starts a fixed-combination product, the incremental value of clindamycin-only products declines.
• That reduces CLINDAGEL upside even if it remains clinically used.

What is CLINDAGEL’s financial trajectory pattern?

Observed trajectory for similar legacy topical acne brands

In markets where multiple generics exist, topical acne brands often show:

• Early plateau after launch, followed by a structural revenue decline after generic entry.
• Partial stabilization when the brand holds formulary preference and maintains adherence-driven demand.
• Renewed decline after subsequent generics and competitive fixed combinations take share.

How to interpret “stable market” signals

A stable number of prescriptions alongside falling net sales typically signals:

• Share shift to lower-priced equivalents within the same active ingredient class.
• Increased discounting by channels.
• Lower realized price due to payer and pharmacy contracting.

Market outlook: what should investors model?

Base case drivers

• Ongoing generic competition keeps realized price under pressure.
• Acne standard of care continues shifting toward combination regimens and antibiotic stewardship.
• Competitive pressure remains high from non-antibiotic therapies and fixed-dose combinations that better align with payer and guideline pathways.

Bull case drivers

• Maintained preferred positioning in key geographies.
• Formulation or packaging that reduces adherence barriers and keeps a segment of prescribers stable.
• Inclusion in pathway-approved regimens that preserve usage.

Bear case drivers

• Further tier downgrades by PBMs and health systems.
• Increased substitution to lower-cost generics and fixed combinations.
• Tightening payer controls that reduce monotherapy use of topical antibiotics.

Regulatory and stewardship factors impacting commercial performance

Antibiotic resistance stewardship

Topical antibiotic use has continued regulatory and guideline scrutiny. In commercial terms:

• Markets may implement usage restrictions or pathway preferences.
• Physicians can shift toward alternatives even without forced regulatory limits.

Safety and labeling

Topical clindamycin has known class considerations (including risks tied to antibiotic exposure). Even when labeling does not change frequently, stewardship messaging influences prescribing and, indirectly, reimbursement.

Where does CLINDAGEL sit on the value chain?

Positioning vs system-level value

CLINDAGEL is not a specialty high-RTx biologic. Its commercial leverage is:

• High volume.
• Moderate clinical differentiation.
• Strong dependence on reimbursement and price contracting.

Value drivers

• Realized price after rebates and discounts.
• Formulary placement and substitution rules.
• Channel behavior (PBM, retail switching, and dermatologist clinic formularies).

Comparable financial dynamics: topical acne legacy brands

Even without CLINDAGEL-specific audited financials in this dataset, the class-wide pattern for topical acne legacy brands holds:

• Generic entry drives long-tail erosion of net revenue.
• Fixed-combination products can accelerate share loss by capturing “regimen selection” rather than “ingredient selection.”
• Brand survival depends less on science and more on contracting and pathway fit.

What to monitor for near-term market shifts

1. Formulary tier movement and rebate changes in major PBM contracts.
2. Share shifts from clindamycin monotherapy to benzoyl peroxide combinations or non-antibiotic alternatives.
3. Retail switching patterns in response to co-pay and lowest-available pricing.
4. Packaging changes that affect dosing convenience and adherence.

---

Key Takeaways

• CLINDAGEL’s market dynamics are dominated by structural generic competition and class-wide antibiotic stewardship pressures.
• Revenue trajectory in topical acne typically tracks realized price compression and formulary tier shifts more than clinical demand.
• Upside is constrained by preference for combination regimens and non-antibiotic alternatives, which can displace clindamycin-only products.
• Short-cycle changes in PBM and health-system coverage can cause meaningful swings in effective demand even without changes to the active ingredient.

FAQs

1. What is CLINDAGEL’s main demand driver? Acne prescribing behavior and the product’s formulary status for topical clindamycin therapy.
2. Why does generic entry matter so much for CLINDAGEL? Topical acne is price sensitive and typically sees fast retail substitution to lower-cost equivalents, compressing realized net price.
3. Does stewardship guidance affect CLINDAGEL usage? Yes, because it can shift prescribers toward combination regimens and limit antibiotic monotherapy, reducing addressable share.
4. What is the biggest financial risk for CLINDAGEL? Further payer tier downgrades and continued share migration to fixed-dose combinations and non-antibiotic regimens.
5. What metric best tracks CLINDAGEL’s trajectory? Realized net sales and pharmacy channel share under PBM contracting, not just prescription counts.

References

[1] Food and Drug Administration. Acne Vulgaris (and topical antibiotic prescribing context). FDA drug labeling and public resources. https://www.fda.gov/ (accessed 2026-04-26)
[2] American Academy of Dermatology. Acne clinical guidance and treatment recommendations. https://www.aad.org/ (accessed 2026-04-26)
[3] National Library of Medicine. Clindamycin phosphate topical information and related acne therapy literature. https://pubmed.ncbi.nlm.nih.gov/ (accessed 2026-04-26)